CXCL14 suppresses the progression of colon cancer by regulating tumor epithelial-mesenchymal transition and tumor microenvironment [Tumor]
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1079209 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR28046725.fastq.gz | Fastqsanger.gz | |||
| SRR28046726.fastq.gz | Fastqsanger.gz | |||
| SRR28046727.fastq.gz | Fastqsanger.gz | |||
| SRR28046728.fastq.gz | Fastqsanger.gz | |||
| SRR28046729.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 8 |
Similar Datasets
Project description:Background：The widespread silencing of CXCL14 in advanced colon cancer underscores the association between CXCL14 and the development of colon cancer. Some studies have demonstrated in vitro that CXCL14 can inhibit the growth and metastasis of colon cancer cell, and it has also been studied in other disease models for its regulation of immune cell infiltration. Aims: The aim of this study is to clarify the transcriptional regulation of colon cancer cells mediated by CXCL14 and its regulatory role in the tumor microenvironment. Method：We analyzed the expression characteristics of CXCL14 in clinical databases of colon cancer. CXCL14 overexpression cell lines were established to study its functions on gene transcriptional regulation and cell physiology. Through subcutaneous tumor models, we investigated the effects of CXCL14 on the immune microenvironment. Result：Firstly, the clinical data revealed that CXCL14 is silenced during cancer progression, and negatively associated with EMT and cell proliferation markers, and positively associated with the abundance of T cells and NK cells in colon tissue. Secondly, RNA-seq reveals that CXCL14 overexpression is negatively associated with cell EMT, and inhibits tumor migration and invasion. Western blot (WB) assay confirmed that CXCL14 inhibits the Erk/MAPK and Akt signaling pathways. Finally, subcutaneous tumor models demonstrate that CXCL14 overexpression inhibited tumor growth, increased the infiltration of tumor-associated T cells and DC cells, activated the anti-tumor immune response, antigen processing and presentation, and T helper differentiation in the tumor microenvironment. Conclusion：CXCL14 becomes silenced in late-stage colon cancer samples. In vivo and in vitro experiments demonstrate that CXCL14 inhibits tumor EMT, proliferation, and metastasis through autocrine signaling. It also enhances the infiltration of T and NK lymphocytes through paracrine signaling and inhibits the proliferation of subcutaneous tumors.
2025-02-01 | GSE256328 | GEO
Project description:Background：The widespread silencing of CXCL14 in advanced colon cancer underscores the association between CXCL14 and the development of colon cancer. Some studies have demonstrated in vitro that CXCL14 can inhibit the growth and metastasis of colon cancer cell, and it has also been studied in other disease models for its regulation of immune cell infiltration. Aims: The aim of this study is to clarify the transcriptional regulation of colon cancer cells mediated by CXCL14 and its regulatory role in the tumor microenvironment. Method：We analyzed the expression characteristics of CXCL14 in clinical databases of colon cancer. CXCL14 overexpression cell lines were established to study its functions on gene transcriptional regulation and cell physiology. Through subcutaneous tumor models, we investigated the effects of CXCL14 on the immune microenvironment. Result：Firstly, the clinical data revealed that CXCL14 is silenced during cancer progression, and negatively associated with EMT and cell proliferation markers, and positively associated with the abundance of T cells and NK cells in colon tissue. Secondly, RNA-seq reveals that CXCL14 overexpression is negatively associated with cell EMT, and inhibits tumor migration and invasion. Western blot (WB) assay confirmed that CXCL14 inhibits the Erk/MAPK and Akt signaling pathways. Finally, subcutaneous tumor models demonstrate that CXCL14 overexpression inhibited tumor growth, increased the infiltration of tumor-associated T cells and DC cells, activated the anti-tumor immune response, antigen processing and presentation, and T helper differentiation in the tumor microenvironment. Conclusion：CXCL14 becomes silenced in late-stage colon cancer samples. In vivo and in vitro experiments demonstrate that CXCL14 inhibits tumor EMT, proliferation, and metastasis through autocrine signaling. It also enhances the infiltration of T and NK lymphocytes through paracrine signaling and inhibits the proliferation of subcutaneous tumors.
2025-02-01 | GSE256330 | GEO
Project description:CXCL14 suppresses the progression of colon cancer by regulating tumor epithelial-mesenchymal transition and tumor microenvironment [MC38-CXCL14]
| PRJNA1079204 | ENA
Project description:Hypoxia-inducible factor-1α (HIF1α) attenuates mitochondrial activity while promoting glycolysis. Paradoxically, it remains unknown why lower glycolysis is compromised in human clear cell renal cell carcinomas (ccRCC), in which HIF1α acts a tumor suppressor by inhibiting cell autonomous proliferation. Here we found that unexpectedly, HIF1α suppresses lower glycolysis after the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) step, leading to reduced lactate secretion in different tumor cell types when cells encounter a limited pyruvate supply such as that typically found in the tumor microenvironment in vivo. This is because HIF1α-dependent attenuation of mitochondrial oxygen consumption increases the NADH/NAD+ ratio that suppresses the activity of NADH-sensitive GAPDH glycolytic enzyme. This is manifested when pyruvate supply is limited since pyruvate acts as an electron acceptor that prevents the increment of the NADH/NAD+ ratio. Furthermore, this anti-glycolytic function provides a molecular basis to explain how HIF1α can suppress tumor cell proliferation by increasing the NADH/NAD+ ratio.
2024-03-15 | MTBLS8901 | MetaboLights
Project description:Monocytic leukemia cell line, THP-1 cells are known to respond to CXCL14. To identfy transcriptional regulation of CXCL14 signalling, we analyse gene expression changed with CXCL14 treatment. THP-1 treated with CXCL14 or PBS treated sample were used.
2013-12-17 | E-GEOD-44550 | biostudies-arrayexpress
Project description:Monocytic leukemia cell line, THP-1 cells are known to respond to CXCL14. To identfy transcriptional regulation of CXCL14 signalling, we analyse gene expression changed with CXCL14 treatment.
2013-12-17 | GSE44550 | GEO
Project description:Neuregulin 4 suppresses NASH-associated liver cancer through restraining tumor-prone liver microenvironment
| PRJNA767430 | ENA
Project description:Low grade serous ovarian cancer (LGSC) is a rare subtype of ovarian cancer, characterized by a slow growth rate, resistance to current treatment regimens, multiple recurrences and poor survival. LGSC arise from serous borderline tumor (SBT), however the mechanism of transformation is poorly understood. To better understand the biology of serous ovarian tumors, we performed whole proteome profiling of LGSC, SBT and the more common high grade serous (HGSC) ovarian tumors. Proteins associated with the tumor microenvironment were differentially expressed between LGSC and SBT or HGSC. In particular, fibroblast activation protein (FAP), a protein expressed in cancer associated fibroblasts, is abundantly expressed in LGSC. Furthermore, Tregs and M2 macrophages are more abundant in the stroma of LGSC compared to SBT. Together these data suggest that the tumor microenvironment provides a supportive environment for LGSC tumorigenesis and progression, and that targeting the tumor microenvironment of LGSC may be a viable therapeutic strategy.
2024-08-15 | PXD046360 | Pride
Project description:Cxcl14+/- mice were mated with Cxcl14+/- mice, the embryos of pregnant females were collected on E13.5. After genotyping, the maternal part and fetal part of Cxcl14-/- and Cxcl14+/+ placentas were dissect out to extract total RNA respectively (n = 3). Total RNA was extracted using PureYield™ RNA Midiprep System (Promega).The maternal part of placenta that contained mesometrial lymphoid aggregate of pregnancy (MLAp) and decidua basalis (DB); the fetal part ofplacenta consisted of spongiotrophoblast and labyrinthin layer.Microarray hybridization was performed using a Mouse NimbleGen cDNA Microarray Kit (Roche), at CapitalBio Co., Ltd.(Beijing,China). Primary data were scaned using NimbleGen MS200 (Roche), and then extracted using NimbleScan system (Roche). Cxcl14+/- mice were mated with Cxcl14+/- mice, the embryos of pregnant females were collected on E13.5. After genotyping, the maternal part and fetal part of Cxcl14-/- and Cxcl14+/+ placentas were dissect out to extract total RNA respectively (n = 3). Total RNA was extracted using PureYield™ RNA Midiprep System (Promega).The maternal part of placenta that contained mesometrial lymphoid aggregate of pregnancy (MLAp) and decidua basalis (DB); the fetal part ofplacenta consisted of spongiotrophoblast and labyrinthin layer.Microarray hybridization was performed using a Mouse NimbleGen cDNA Microarray Kit (Roche), at CapitalBio Co., Ltd.(Beijing,China). Primary data were scaned using NimbleGen MS200 (Roche), and then extracted using NimbleScan system (Roche).
2013-06-19 | E-GEOD-48095 | biostudies-arrayexpress
Project description:PRMT1 suppresses anti-tumor immunity
| PRJNA840921 | ENA